Biopharma's Foundation Provides for Downside Protection, Upside Realization

Research Report
  ()
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. read more >

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases

Research Report
  ()
Analyst expects "transformational year" for company with a phase 3 trial underway. read more >

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise'

Research Report
  ()
A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report. read more >
News Update

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease

News Update
  ()
The Canadian company continues seeking partners to leverage its discovery and development platform. read more >

Biopharma's Drug Well Tolerated in Opioid Withdrawal Study

Research Report
  ()
An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study. read more >
News Update

Medical Device Firm Develops Nitric Oxide Delivery Unit for Clinic Use

News Update
  ()
This new machine takes the company's product line count to four. read more >
News Update

Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments

News Update
  ()
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. read more >

Accelerated Approval Could Be 'Game Changer' for Biotech

Research Report
  ()
This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note. read more >

Lessons from January…This Could Make You Money Someday

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research does a deep dive into his portfolio to discern trends and lessons to be learned. read more >

Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy

Research Report
  ()
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation. read more >
Expert Investing Ideas

"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


"DRRX intends to start a NASH trial as soon as H1/19."

–Francois Brisebois, Laidlaw & Company


"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders

Research Report
  ()
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets. read more >

Anixa Doesn't Disappoint

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. read more >

Early Data for Biotech's Pain Drug Candidate 'Show Promise'

Research Report
  ()
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain. read more >

Commercial Launch Planned for Schizophrenia Drug

  ()
A drug used to treat schizophrenic patients will launch commercially in February in the U.S. read more >